Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68


Fingerprint pattern of bone mineralisation on cemented and uncemented femoral stems: analysis by [18F]-fluoride-PET in a randomised clinical trial.

Ullmark G, Sörensen J, Maripuu E, Nilsson O.

Hip Int. 2018 Dec 6:1120700018815404. doi: 10.1177/1120700018815404. [Epub ahead of print]


miR-203 and miR-320 Regulate Bone Morphogenetic Protein-2-Induced Osteoblast Differentiation by Targeting Distal-Less Homeobox 5 (Dlx5).

Laxman N, Mallmin H, Nilsson O, Kindmark A.

Genes (Basel). 2016 Dec 23;8(1). pii: E4. doi: 10.3390/genes8010004.


Second generation sequencing of microRNA in Human Bone Cells treated with Parathyroid Hormone or Dexamethasone.

Laxman N, Rubin CJ, Mallmin H, Nilsson O, Tellgren-Roth C, Kindmark A.

Bone. 2016 Mar;84:181-188. doi: 10.1016/j.bone.2015.12.053. Epub 2015 Dec 31.


Podocalyxin as a Prognostic Marker in Gastric Cancer.

Laitinen A, Böckelman C, Hagström J, Kokkola A, Fermér C, Nilsson O, Haglund C.

PLoS One. 2015 Dec 16;10(12):e0145079. doi: 10.1371/journal.pone.0145079. eCollection 2015.


Expression of Stem Cell-associated Marker HES77 in Rectal Neuroendocrine Tumors.

Jernman J, Hagström J, Mäenpää H, Välimäki MJ, Haapasalo H, Nilsson O, Fermér C, Haglund C, Arola J.

Anticancer Res. 2015 Jul;35(7):3767-72.


Global miRNA expression and correlation with mRNA levels in primary human bone cells.

Laxman N, Rubin CJ, Mallmin H, Nilsson O, Pastinen T, Grundberg E, Kindmark A.

RNA. 2015 Aug;21(8):1433-43. doi: 10.1261/rna.049148.114. Epub 2015 Jun 15.


Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.

Saukkonen K, Hagström J, Mustonen H, Juuti A, Nordling S, Fermér C, Nilsson O, Seppänen H, Haglund C.

PLoS One. 2015 Jun 8;10(6):e0129012. doi: 10.1371/journal.pone.0129012. eCollection 2015.


A novel stem cell associated marker identified by monoclonal antibody HESC5:3 differentiates between neoplastic lesions in follicular thyroid neoplasms.

Heikkilä A, Fermér C, Hagström J, Louhimo J, Mäenpää H, Siironen P, Heiskanen I, Nilsson O, Arola J, Haglund C.

APMIS. 2015 Jul;123(7):604-12. doi: 10.1111/apm.12393. Epub 2015 May 9.


Legg-Calvé-Perthes disease and the risk of ADHD, depression, and mortality.

Hailer YD, Nilsson O.

Acta Orthop. 2014 Sep;85(5):501-5. doi: 10.3109/17453674.2014.939015. Epub 2014 Jul 18.


A comparative study of two PODXL antibodies in 840 colorectal cancer patients.

Kaprio T, Hagström J, Fermér C, Mustonen H, Böckelman C, Nilsson O, Haglund C.

BMC Cancer. 2014 Jul 8;14:494. doi: 10.1186/1471-2407-14-494.


Podocalyxin is a marker of poor prognosis in colorectal cancer.

Kaprio T, Fermér C, Hagström J, Mustonen H, Böckelman C, Nilsson O, Haglund C.

BMC Cancer. 2014 Jul 8;14:493. doi: 10.1186/1471-2407-14-493.


Comparison of reverse transcription quantitative real-time PCR, flow cytometry, and immunohistochemistry for detection of monoclonality in lymphomas.

Ståhlberg A, Aman P, Strömbom L, Zoric N, Diez A, Nilsson O, Kubista M, Ridell B.

ISRN Oncol. 2014 Feb 4;2014:796210. doi: 10.1155/2014/796210. eCollection 2014.


Analysis of bone mineralization on uncemented femoral stems by [18F]-fluoride-PET: a randomized clinical study of 16 hips in 8 patients.

Ullmark G, Nilsson O, Maripuu E, Sörensen J.

Acta Orthop. 2013 Apr;84(2):138-44. doi: 10.3109/17453674.2013.786632. Epub 2013 Mar 19.


Rats treated with AZD2858, a GSK3 inhibitor, heal fractures rapidly without endochondral bone formation.

Sisask G, Marsell R, Sundgren-Andersson A, Larsson S, Nilsson O, Ljunggren O, Jonsson KB.

Bone. 2013 May;54(1):126-32. doi: 10.1016/j.bone.2013.01.019. Epub 2013 Jan 19.


Suitability of quality control materials for prostate-specific antigen (PSA) measurement: inter-method variability of common tumor marker control materials.

Vucetic Z, Dnistrian A, Nilsson O, Lilja HG, Plebani M.

Clin Chem Lab Med. 2013 Apr;51(4):873-80. doi: 10.1515/cclm-2012-0660.


Analysis of bone formation on porous and calcium phosphate-coated acetabular cups: a randomised clinical [18F]fluoride PET study.

Ullmark G, Sörensen J, Nilsson O.

Hip Int. 2012 Mar-Apr;22(2):172-8. doi: 10.5301/HIP.2012.9233.


Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.

Evans-Axelsson S, Ulmert D, Örbom A, Peterson P, Nilsson O, Wennerberg J, Strand J, Wingårdh K, Olsson T, Hagman Z, Tolmachev V, Bjartell A, Lilja H, Strand SE.

Cancer Biother Radiopharm. 2012 May;27(4):243-51. doi: 10.1089/cbr.2011.1088. Epub 2012 Apr 10.


GSK-3 inhibition by an orally active small molecule increases bone mass in rats.

Marsell R, Sisask G, Nilsson Y, Sundgren-Andersson AK, Andersson U, Larsson S, Nilsson O, Ljunggren O, Jonsson KB.

Bone. 2012 Mar;50(3):619-27. doi: 10.1016/j.bone.2011.11.007. Epub 2011 Nov 25.


Metabolic development of necrotic bone in the femoral head following resurfacing arthroplasty. A clinical [18F]fluoride-PET study in 11 asymptomatic hips.

Ullmark G, Sundgren K, Milbrink J, Nilsson O, Sörensen J.

Acta Orthop. 2012 Feb;83(1):22-5. doi: 10.3109/17453674.2011.641108. Epub 2011 Nov 23.


Detection of human papillomavirus oncoprotein E7 in liquid-based cytology.

Lidqvist M, Nilsson O, Holmgren J, Hölters S, Röijer E, Dürst M, Fermér C.

J Gen Virol. 2012 Feb;93(Pt 2):356-63. doi: 10.1099/vir.0.034884-0. Epub 2011 Oct 19.


Supplemental Content

Loading ...
Support Center